Publication at First Faculty of Medicine, Second Faculty of Medicine |
2019
Abstract
Hypoglycemia is one of the common side effects of KD used in the treatment of patients with drug-resistant epilepsy and also super-refractory status epilepticus. The authors stated that regular glucose monitoring was part of the treatment protocol, but hypoglycemia was not mentioned among the side effects of the therapy.
Could they state what the definition of hypoglycemia was, and its management in the protocol and whether no hypoglycemia was detected in the patients during the treatment? We believe that such information will add substantially to the results of their important study.